Citadel Advisors
RLMD icon

Citadel Advisors’s Relmada Therapeutics RLMD Stock Holding History

Citadel Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,063
Closed -$133K – 14038
2025
Q4 		$136K Buy
+28,063
New +$94K ﹤0.01% 11405
2024
Q4 		– Sell
-52,846
Closed -$129K – 15244
2024
Q3 		$171K Sell
52,846
-31,467
-37% -$102K ﹤0.01% 10381
2024
Q2 		$253K Buy
84,313
+13,769
+20% +$49.8K ﹤0.01% 9471
2024
Q1 		$328K Sell
70,544
-305,114
-81% -$1.47M ﹤0.01% 9265
2023
Q4 		$1.56M Sell
375,658
-56,437
-13% -$167K ﹤0.01% 5823
2023
Q3 		$1.3M Sell
432,095
-155,699
-26% -$462K ﹤0.01% 6047
2023
Q2 		$1.45M Sell
587,794
-82,239
-12% -$227K ﹤0.01% 5743
2023
Q1 		$1.51M Buy
670,033
+401,017
+149% +$1.38M ﹤0.01% 5895
2022
Q4 		$939K Sell
269,016
-661,588
-71% -$5.81M ﹤0.01% 6937
2022
Q3 		$34.5M Sell
930,604
-16,809
-2% -$466K 0.01% 1358
2022
Q2 		$18M Buy
947,413
+7,941
+0.8% +$173K ﹤0.01% 1956
2022
Q1 		$25.4M Buy
939,472
+645,518
+220% +$13.3M 0.01% 1722
2021
Q4 		$6.62M Sell
293,954
-81,898
-22% -$1.82M ﹤0.01% 3811
2021
Q3 		$9.85M Buy
375,852
+12,869
+4% +$344K ﹤0.01% 3109
2021
Q2 		$11.6M Buy
362,983
+352,522
+3,370% +$12.2M ﹤0.01% 2841
2021
Q1 		$368K Buy
10,461
+2,542
+32% +$88.9K ﹤0.01% 10372
2020
Q4 		$254K Buy
+7,919
New +$272K ﹤0.01% 9366
2020
Q2 		– Sell
-320,072
Closed -$10.9M – 10395
2020
Q1 		$10.9M Buy
320,072
+239,906
+299% +$9.67M ﹤0.01% 1763
2019
Q4 		$3.13M Buy
+80,166
New +$2.44M ﹤0.01% 3732

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors's RLMD Position: Q1 2026 in Review

Citadel Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 28,063 shares — an estimated $133K sold.

Citadel Advisors first reported a position in RLMD in Q4 2019 and held it in 19 quarters. The position peaked at $34.5M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Citadel Advisors reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 28,063 Relmada Therapeutics shares in Q1 2026, an estimated $133K.
  • Citadel Advisors first reported a position in Relmada Therapeutics in Q4 2019 and held it in 19 quarters.
  • Citadel Advisors's Relmada Therapeutics position peaked at $34.5M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.